Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185741 · ClinicalTrials.gov registry record · NA
Regimen Education and Messaging in Diabetes (REMinD)
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 767
- Enrollment target
NCT03185741: Completed NA study, sponsored by Northwestern University.
NCT03185741 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 767 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185741, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 767 participants
- Enrollment target
Study Summary
The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health literacy principles and more explicit times to describe when to take medicine (morning, noon, evening, bedtime). This eliminates variability found in the way prescriptions are written by physicians and transcribed by pharmacists onto drug bottle labels. The proposed intervention will standardize prescribing within an electronic health record (EHR) so all medication orders include UMS prescription instructions ('sigs') and patients receive a medication information sheet with their after-visit summaries. Additionally, to help patients remember when to take prescribed medicines we will link unidirectional short message service (SMS) text reminders to the EHR, delivering medication reminders to patients around UMS intervals. 1. Test the effectiveness of the UMS, and UMS + SMS text reminder strategies compared to usual care. 2. Determine if the effects of these UMS strategies vary by patients' literacy skills and language. 3. Using mixed methods, evaluate the fidelity of the two strategies and explore patient, staff, physician, and health system factors influencing the interventions. 4. Assess the costs required to deliver either intervention from a health system perspective.
Primary Outcome
Adherence will be measured for each prescription medication using an objective pill count of the number of pills within each prescription bottle. The proportion of pills taken over pills prescribed (PT/PP) will be calculated for each medication at baseline and 6Month. Pills taken will be calculated by subtracting the number of pills from the total quantity prescribed. Pills prescribed will be calculated by multiplying the number of pills prescribed each day by the number of days since the medica
Interventions
- BEHAVIORAL SMS Text Messaging
- BEHAVIORAL UMS Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2022-11-30 |
| Phase | NA |
What the finished NCT03185741 record still lists
NCT03185741 is an interventional study that assigns participants to a tested intervention. The registered 767 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which SMS Text Messaging is the first listed.
NCT03185741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185741 about?
NCT03185741 is a clinical study titled "Regimen Education and Messaging in Diabetes (REMinD)". The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health li...
What is the current status of trial NCT03185741?
This trial is currently completed. It is a NA study. The enrollment target is 767 participants. The study started on 2018-01-05. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT03185741?
The interventions under investigation include: SMS Text Messaging (BEHAVIORAL), UMS Strategy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03185741?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03185741's enrollment target sits among peer trials
767 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI